1919 Investment Counsel’s Alexion Pharmaceuticals ALXN Stock Holding History

1919 Investment Counsel’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$32.1M	Buy	193,772 +118,380	+157%	+$19.4M	0.66%	47
2014 Q2	$11.8M	Buy	75,392 +6,566	+10%	+$1.04M	0.24%	100
2014 Q1	$10.5M	Buy	68,826 +45,074	+190%	+$7.17M	0.21%	102
2013 Q4	$3.16M	Buy	23,752 +21,273	+858%	+$2.55M	0.07%	230
2013 Q3	$288K	Hold	2,479	–	–	0.01%	480
2013 Q2	$229K	Buy	+2,479	New	+$239K	0.01%	487

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

1919 Investment Counsel's ALXN Position: Q3 2014 in Review

1919 Investment Counsel increased its Alexion Pharmaceuticals (ALXN) stake by 157% in Q3 2014, buying an estimated $19.4M and bringing the position to 193,772 shares worth $32.1M. The position accounts for 0.66% of the portfolio, ranked #47.

1919 Investment Counsel first reported a position in ALXN in Q2 2013 and has held it in 6 quarters since. 522 funds tracked by Wall St. Rank hold ALXN as of Q3 2014.

1919 Investment Counsel held 193,772 shares of Alexion Pharmaceuticals worth $32.1M as of Q3 2014.
1919 Investment Counsel bought 118,380 Alexion Pharmaceuticals shares in Q3 2014, an estimated $19.4M.
Alexion Pharmaceuticals made up 0.66% of 1919 Investment Counsel's portfolio in Q3 2014, its #47 holding.
1919 Investment Counsel first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
522 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2014.

Based on 1919 Investment Counsel's 13F filing for Q3 2014, filed 14 Nov 2014.